Author:
Mustafa Suzana,Mustafa Mahiran,Wan Yusuf Wan Nazirah
Abstract
Introduction: The HIV epidemic in Malaysia predominantly affects males (90% of total HIV cases) mostly intravenous drugs users. Nevirapine-based of highly active antiretroviral therapy (HAART) once- or twice-daily dosage improve accessibility and effectiveness of antiretroviral treatment for HIV positive intravenous drug users (IDUs) receiving methadone maintenance treatment. Studies reported that concomitant administration of nevirapine with methadone reduced methadone plasma concentration. Since methadone and nevirapine were both known to be the substrate for cytochrome 2B6 (CYP 2B6), concomitant use of both drugs may affect nevirapine concentration too. However, methadone effect on nevirapine concentration is still unclear. This is a cross sectional study which reports how methadone co-administration affects the pharmacokinetic parameters of nevirapine in people living with HIV (PLHIV). Methods: 112 patients receiving nevirapine-based antiretroviral drugs were recruited. Seventeen were maintained with methadone without withdrawal symptoms. High-performance liquid chromatography was used to measure plasma nevirapine concentrations. Nevirapine population pharmacokinetics was modelled with a non-parametric approach using Pmetrics software. Result: According to univariate analysis, concurrent methadone administration increased the clearance of nevirapine by 25.3% (p = 0.046). Multivariate analysis showed that methadone medication was independently linked with lower nevirapine concentrations and area-under-curve (Cmin was reduced by 15.2%, p = 0.011, Cmax 19.5%; p = 0.003, AUC12 16.2%; p = 0.021 respectively). Conclusion: This study provides in-vivo evidence of methadone co-administration reducing nevirapine exposure. Since a low concentration of nevirapine will lead to treatment failure, monitoring is essential for PLHIV using both medications at the same time.
Publisher
Universiti Putra Malaysia
Reference36 articles.
1. 1. World Health Organization. Latest HIV estimates and updates on HIV policies uptake. Glob HIV, Hepat STI Program [Internet]. 2020;(November):1–40. Available from: https://www.who.int/docs/default-source/hiv-hq/latest-hiv-estimates-and-updates-on-hiv-policies-uptake-november2020.pdf?sfvrsn=10a0043d_12
2. 2. Goh KL, Chua CT, Chiew IS, Soo-Hoo TS. The acquired immune deficiency syndrome: a report of the first case in Malaysia. Med J Malaysia. 1987 Mar;42(1):58–60.
3. 3. MOH M. Global AIDS Monitoring 2020 Malaysia HIV/AIDS Progress Report. 2020;1–27. Available from: https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf
4. 4. Mondal MNI, Shitan M. HIV/AIDS epidemic in Malaysia : vulnerability and risk of women. Asian Journal of Humanities and Social Studies. Asian Online Journals 2013; 1(5):274-283.
5. 5. Kwee Choy Koh. A review of HIV/AIDS Research in Malaysia. Med J Malaysia [Internet]. 2014;69(August):68–81. Available from: http://www.embase.com/search/results?subaction=view record&from=export&id=L600485704